Back to Browse Journals » Orphan Drugs: Research and Reviews » Volume 6

Adverse events reported for hereditary angioedema medications: a retrospective study of spontaneous reports submitted to the EudraVigilance database, 2007-2013

Authors Aagaard L, Bygum A

Received 19 August 2015

Accepted for publication 29 January 2016

Published 3 May 2016 Volume 2016:6 Pages 1—8

DOI https://doi.org/10.2147/ODRR.S94790

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Deepak Bhasin

Peer reviewer comments 4

Editor who approved publication: Professor Abdel Abdel-Rahman

Lise Aagaard,1 Anette Bygum,2
1Section for Clinical Pharmacology, Institute of Public Health, Faculty of Health Sciences, University of Southern Denmark, 2Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark

Abstract:
Information about long-term safety issues from use of orphan drugs in treatment of hereditary angioedema (HAE) is limited and must be studied further. As clinical trials in patients with rare diseases are limited, prescribers and patients have to rely on spontaneous adverse drug reaction (ADR) reports for obtaining major information about the serious, rarely occurring, and unknown ADRs. In this study, we aimed to characterize ADRs reported for HAE medications in Europe from 2007 to 2013. ADR reports submitted for C1-inibitors and bradykinin receptor antagonists to the European ADR database, EudraVigilance (EV), were included in this study. The ADR reports were categorized with respect to age and sex of the patients, category of the reporter, type and seriousness of the reported ADRs, and medications. The unit of analysis was one adverse event (AE). Totally, 187 AEs were located in EV, and of these, 138 AEs were reported for Cinryze® (C1-inhibitor) (73% of the total) and 49 AEs for Firazyr® (icatibant) (26% of the total AEs). Approximately 60% of all AEs were serious, including three fatal cases. Less than 5% of AEs were reported in children. In total, 62% of AEs were reported for women and 38% for men. For both Cinryze® and Firazyr®, the majority of reported AEs were of the type “general disorders and administration site conditions”. For Cinryze®, a large number of AEs of the type “HAE” and “drug ineffective” was reported, but only few of these were serious. For Firazyr®, several nonserious reports on injection site reactions were reported. In conclusion, this study showed that in EV, several ADR reports from use of HAE medications were identified, and a large number of these were serious, including fatal cases.

Keywords: orphan drugs, hereditary angioedema, adverse drug reactions, adverse events, C1-inhibitor, Cinryze®, icatibant, Firazyr®, EudraVigilance

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Assisted ventilation in COPD – association between previous hospitalizations and mortality

Toft-Petersen AP, Torp-Pedersen C, Weinreich UM, Rasmussen BS

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:935-943

Published Date: 3 May 2016

Delivery of a survivin promoter-driven antisense survivin-expressing plasmid DNA as a cancer therapeutic: a proof-of-concept study

Lin KY, Cheng SM, Tsai SL, Tsai JY, Lin CH, Cheung CHA

OncoTargets and Therapy 2016, 9:2601-2613

Published Date: 3 May 2016

Factors affecting treatment adherence to atomoxetine in ADHD: a systematic review

Treuer T, Méndez L, Montgomery W, Wu S

Neuropsychiatric Disease and Treatment 2016, 12:1061-1083

Published Date: 3 May 2016

Design, synthesis, and biological evaluation of 3-vinyl-quinoxalin-2(1H)-one derivatives as novel antitumor inhibitors of FGFR1

Liu Z, Yu S, Chen D, Shen G, Wang Y, Hou L, Lin D, Zhang JS, Ye F

Drug Design, Development and Therapy 2016, 10:1489-1500

Published Date: 3 May 2016